BioForest
Filter News
Found 19,403 articles
-
BioSpace Hotbed maps have been a life sciences industry staple for over 30 years. Today the program features eight regional Hotbed Maps and the NextGen Bio Map which highlights some of the industry’s most promising startups.
-
Like the Grinch’s heart at Christmas, the Nasdaq Exchange grew a little bigger this week with multiple life science companies raising hundreds of millions of dollars in initial public offerings.
-
Silverback Therapeutics Announces Pricing of Initial Public Offering - Dec 04, 2020
12/4/2020
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, announced the pricing of its initial public offering of 11,500,000 shares of its common stock at a price to the public of $21.00 per share.
-
Seattle Cancer Care Alliance to Present New Research at 62nd Annual Meeting of the American Society of Hematology
12/4/2020
Seattle Cancer Care Alliance (SCCA), the only National Comprehensive Cancer Network (NCCN)-designated cancer center in Washington state, announced that its clinicians will present new research at the 62nd Annual Meeting of the American Society of Hematology, which is being held virtually December 5-8, 2020.
-
As if attempting to steal hard-won research wasn’t bad enough, hackers are now hitting people where it really hurts – with e-documents containing malicious code embedded in false offers of employment.
-
Upping the numbers two times, Silverback now readies a 10 million share offering.
-
Know Labs Provides Update on Company Business, Impact of Covid-19
12/3/2020
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, announced that its efforts to test and validate its patented Bio-RFID™ platform technology for non-invasive glucose monitoring with third-party research organizations have been temporarily slowed by the impact of Covid-19.
-
CMS Confirms Continued Separate Payment for Omeros’ FDA-Approved OMIDRIA® in Ambulatory Surgery Centers
12/3/2020
Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Omeros’ cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%.
-
Washington State University Health Sciences Launches Life Sciences Incubator, sp3nw, Supported by $250,000 Grant From Bank of America
12/3/2020
sp3nw to Accelerate WSU Life Science Innovation and Entrepreneurship Into Biotech, Pharma, Diagnostics, and Medical Device Companies Through Faculty, Affiliate Expertise
-
Achieve Life Sciences Announces Pricing of $15 Million Public Offering
12/3/2020
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of 2,150,000 shares of its common stock at a price
-
Shape Therapeutics Unveils AAVid™ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene Therapy
12/3/2020
Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the unveiling of the AAVidTM capsid discovery platform and results from its first AAV5 variant library in a non-human primate selection campaign.
-
New Survey Highlights Consumer Concerns Over How Travel Companies Sanitize
12/2/2020
Vioguard, a Leader in UV-C Technology Conducts Survey to Gauge Perspectives on Travel During the Pandemic
-
Spinal Industry Innovator joins Proprio as Advisor
12/2/2020
Proprio announced that spinal industry veteran Tommy Carls has joined as an advisor to the company.
-
Aptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX(TM) and Introduces the New Bispecific Prostate Cancer Candidate APVO442
12/2/2020
APVO442 is a Unique T-Cell Engager Designed to Target PSMA and CD3 for the Treatment of Prostate Cancer
-
AVM Biotechnology President Selected to Speak at ESWI Conference in Novel and Outstanding Discoveries Track
12/2/2020
AVM Biotechnology, a company developing a proprietary and innovative form of dexamethasone, today announced that CEO/CSO, Dr. Theresa Deisher has been selected to present during the Novel and Outstanding Discoveries Track at the European Scientific Working Group on Influenza (ESWI). The ESWI 2020 Virtual Conference will run from Decemb
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 1, 2020.
-
CarepathRx and UPMC Announce Landmark Partnership to Bring Comprehensive Pharmacy Care Solutions to More Patients
12/1/2020
CarepathRx, a leader in pharmacy and medication management solutions for vulnerable and chronically ill patients, announced a partnership with UPMC's Chartwell subsidiary that will expand patient access to innovative specialty pharmacy and home infusion services.
-
Nanodropper Cofounders Named Honorees of 2021 Forbes 30 Under 30 List
12/1/2020
The Nanodropper cofounding team of Mackenzie Andrews , Elias Baker , Allisa Song , and Jennifer Steger , PhD, have been named to the 2021 Forbes 30 Under 30 list. Nanodropper is a medical device company offering a first-of-its-kind eyedrop bottle adaptor that reduces droplet size, which is currently saving patients and clinics a
-
Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimer’s Disease
12/1/2020
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in ACT-AD, a Phase 2 randomized, placebo-controlled study of ATH-1017 in patients with mild-to-moderate Alzheimer's disease
-
BioLife Solutions & Casdin Capital Innovation Accelerator Announce New Investments in Cell & Gene Therapy Bioproduction Tools
12/1/2020
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced two new co-investments with innovation accelerator partner Casdin Capital.